Prevention of Organ Transplant Rejection: Current Therapies and Novel StrategiesDecision ResourcesSeptember 14, 2005 14 Pages - SKU: DECR1212091 |
| The practice of organ transplantation has expanded substantially since the first successful kidney transplant, more than 40 years ago. Despite improvements in the rate of acute organ rejection following transplantation, however, organ loss remains a problem. Approximately 50% of the $5 billion spent annually in the United States on organ transplants is spent on post-transplantation immunosuppressive therapy and/or treatment of complications following transplantation, including acute and chronic rejection. In this report, we examine the causes of acute and chronic organ rejection and discuss the benefits and drawbacks of current treatment options. We review emerging targets for rejection therapies and discuss the strategic transition from immunosuppression to immunomodulation. Finally, we profile several drugs in clinical development that we expect will change the standard of care for transplant patients by 2010. Please note: the PDF e-mail from publisher version of this report is for a global site license. |
